Alzheimer's disease (AD) is characterized by two molecular pathologies: cerebral β-
amyloidosis in the form of β-amyloid (Aβ) plaques and tauopathy in the form of neurofibrillary …

The clinical heterogeneity of Alzheimer's disease is not reflected in the rather diffuse cortical
deposition of amyloidß. We assessed the relationship between clinical symptoms, in vivo tau …

The amyloid cascade model of Alzheimer's disease posits the primacy of amyloid beta
deposition preceding tau-mediated neurofibrillary tangle formation. The amyloid-tau …

β-Amyloid plaques and tau-containing neurofibrillary tangles are the two neuropathological
hallmarks of Alzheimer's disease (AD) and are thought to play crucial roles in a …

See Sarazin et al.(doi: 10.1093/brain/aww041) for a scientific commentary on this article.
The advent of the positron emission tomography tracer 18 F-AV1451 provides the unique …

Importance Positron emission tomography (PET) imaging now allows in vivo visualization of
both neuropathologic hallmarks of Alzheimer disease (AD): amyloid-β (Aβ) plaques and tau …

Abstract Utilizing [18F]-AV-1451 tau positron emission tomography (PET) as an Alzheimer
disease (AD) biomarker will require identification of brain regions that are most important in …

Introduction Neuroimaging modalities can measure different aspects of the disease process
in Alzheimer's disease, although the relationship between these modalities is unclear …

Objective To determine the in vivo cortical spreading pattern of tau and amyloid and to
establish positron emission tomography (PET) image‐based tau staging in the Alzheimer …

Neuropathological and in vivo studies have revealed a tight relationship between tau
pathology and cognitive impairment across the Alzheimer's disease spectrum. However, tau …